Tilray Brands, Inc. (TLRY) Stock Price & Analysis
Tilray Brands, Inc. (TLRY) is trading at USD 2.84, down 3.24% today, as of October 23, 2026 at 16:18 UTC (US market open; quotes may be delayed), according to Nexqual market data.
TLRY last closed at USD 2.84; today's session has ranged USD 2.8–2.93 on volume of 1,844,362 shares. Market capitalization is —, with a 52-week range of USD 2.8–15.7 (NMS). Source: Nexqual, retrieved October 23, 2026 at 16:18 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TLRY.md
Key facts (TLRY)
- Last four reported quarters (through Aug 31, 2026): revenue $963M, net income -$164M (-17.1% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $233K; 1 not under a Rule 10b5-1 plan ($233K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $69K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -80.8% vs S&P 500 +14.7%; 5Y -97.3% vs S&P 500 +77.5%.
- Next earnings: 2027-01-07, EPS estimate USD 0, revenue estimate $265M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TLRY)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $628M | $627M | $789M | $821M | $915M | $963M |
| Gross profit | $117M | $147M | $223M | $241M | $260M | — |
| Operating income | -$610M | -$1.37B | -$175M | -$2.28B | -$63.0M | -$89.2M |
| Net income | -$477M | -$1.45B | -$245M | -$2.19B | -$121M | -$164M |
| EPS (diluted) | -$9.90 | -$23.50 | -$3.30 | -$24.56 | -$1.09 | — |
| Free cash flow | -$211M | -$12.9M | -$60.2M | -$128M | — | — |
| Gross margin | 18.6% | 23.4% | 28.3% | 29.3% | 28.4% | — |
| Operating margin | -97.1% | -218.4% | -22.1% | -277.9% | -6.9% | -9.3% |
| Net margin | -75.9% | -231.6% | -31.1% | -266.3% | -13.3% | -17.1% |
| Revenue growth | +22.5% | -0.2% | +25.8% | +4.1% | +11.5% | — |
| Cash + short-term investments | $416M | $449M | $261M | $256M | $231M | — |
| Total debt | $186M | $244M | $148M | $93.6M | $129M | — |
Fiscal years end May. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Aug 31, 2026) (TLRY)
Insider sales (SEC Form 4, open-market, last ~7 months) (TLRY)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-04-21 | Hopkinson David G. | Director | 33,556 | $233K | 100% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (TLRY)
3 purchases, $69K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-06 | Gendel Mitchell | Global General Counsel | 2,500 | $11K | 4.43 | Too little history (no open-market trades in 2023) |
| 2026-08-04 | Merton Carl A | Chief Financial Officer | 10,000 | $46K | 4.62 | Too little history (no open-market trades in 2023) |
| 2026-08-03 | Faltischek Denise M | Chief Strategy Officer | 2,500 | $12K | 4.78 | Too little history (no open-market trades in 2023 or 2025) |
Analysts (TLRY)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Canaccord Genuity | Target lowered | Hold | $4.5 → $4 |
| 2026-07-14 | TD Cowen | Target lowered | Buy | $7 → $5 |
Total return (dividends reinvested) (TLRY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -80.8% | -97.3% |
| S&P 500 (SPY) | +14.7% | +77.5% |
| Per year | -80.9% | -51.3% |
| Volatility (annualized) | 77.3% | 79.7% |
| Max drawdown | -81.0% (Oct 2025→Oct 2026) | -97.8% (Nov 2021→Oct 2026) |
TLRY revenue by business segment (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Beverage Alcohol Business | $101.5M | 39.5% | +82.1% |
| Distribution Business | $84.3M | 32.8% | +13.9% |
| Cannabis | $56.1M | 21.8% | -13.0% |
| Wellness Business | $15.3M | 5.9% | +0.2% |
| Total revenue | $257.1M | 100% | — |
TLRY revenue by product line (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Adultuse Cannabis Products | $53.6M | 20.8% | -16.4% |
| International Cannabis Products | $16.2M | 6.3% | +21.5% |
| Medical Cannabis Products | $4.7M | 1.8% | -23.3% |
| Wholesale Cannabis Products | $673,000 | 0.3% | -83.8% |
| Total revenue | $257.1M | 100% | — |
TLRY revenue by region (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| EMEA | $145.5M | 56.6% | +70.7% |
| United States | $58.3M | 22.7% | -8.8% |
| Canada | $48.4M | 18.8% | -16.7% |
| Rest Of World | $4.9M | 1.9% | +129.6% |
| Total revenue | $257.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
TLRY suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | CC Pharma | “CC Pharma also supports our medical cannabis business in Germany by providing packaging, order fulfillment, customer service, warehousing, and logistics services.” |
Quoted from the company's 10-K filed Jul 28, 2026.
TLRY company outlook (results filed Oct 8, 2026)
- “Guidance of $68 Million to $75 Million NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
TLRY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Nov 2026) | $0.00 | $0.00 | — | $265.0M | 1 |
| Next quarter (ends Feb 2027) | $0.00 | $0.00 | — | $265.6M | 1 |
| Current fiscal year (ends May 2027) | $-0.13 | $0.26 | -150.2% | $1.10B | 2 |
| Next fiscal year (ends May 2028) | $0.14 | $0.74 | -80.8% | $1.16B | 2 |
Key Statistics (as of October 23, 2026 at 16:18 UTC)
| Price | USD 2.84 |
|---|---|
| Change | ▼ 3.24% (down) |
| Previous Close | USD 2.84 |
| Open | USD 2.84 |
| Day Range | USD 2.8 – 2.93 |
| 52-Week Range | USD 2.8 – 15.7 |
| Volume | 1,844,362 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (TLRY)
Nexqual's technical model rates TLRY "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 16:18 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 20.5 (oversold) |
| vs SMA50 | Below (USD 3.99) |
| MACD | -0.32 (negative) |
Earnings (TLRY)
| Next Earnings Date | 2027-01-07 |
|---|---|
| EPS Estimate | USD 0 |
| Revenue Estimate | $264.98M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-08-31 | USD -0.02 vs est -0.14 ▲ beat |
| 2026-05-31 | USD 0.05 vs est 0.21 ▼ miss |
| 2026-02-28 | USD 0.02 vs est 0.07 ▼ miss |
| 2025-11-30 | USD -0.02 vs est 0 ▼ miss |
Source: Nexqual, October 23, 2026 at 16:18 UTC.
Financials & Fundamentals (TLRY)
| Total Revenue | $963.10M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +22.70% |
| Gross Margin | +29.35% |
| Operating Margin | -6.23% |
| Profit Margin | -17.05% |
| ROE | -9.38% |
| Debt / Equity | 0.23 |
| Current Ratio | 1.88 |
| Total Cash | $218.01M |
| Total Debt | $371.93M |
Source: Nexqual, October 23, 2026 at 16:18 UTC.
Ownership (TLRY)
| Insider Ownership | +1.59% |
|---|---|
| Institutional Ownership | +10.16% |
| Shares Outstanding | 147.79M |
| Float | 144.36M |
| Short % of Float | +12.92% |
Source: Nexqual, October 23, 2026 at 16:18 UTC.
From Tilray Brands, Inc.'s Latest SEC 10-K Filing (filed 2026-07-28)
Key Strengths & Strategy (as disclosed to the SEC)
- The 2018 Farm Bill preserves the authority and jurisdiction of the Food and Drug Administration (the "FDA"), under the Food Drug & Cosmetic Act (the "FD&C Act"), to regulate the manufacture, marketing, and sale of food, drugs, dietary supplements, and cosmetics, including products that contain Hemp extracts and derivatives, such as CBD.
- With a focus on brand building, innovation, loyalty and conversion, we seek to drive growth with our differentiated portfolio of brands and products, both in sales and market share across categories.
- We also made significant investments in our operations within Europe and we are well-positioned to pursue international growth opportunities with our strong medical cannabis brands, distribution network in Germany, and end-to-end European Union Good Manufacturing Practices ("EU-GMP") supply chain, which includes EU-GMP production facilities in Portugal and Germany.
- The addition of Lyphe strengthens Tilray's vertically integrated medical ecosystem by combining clinical services, patient access, and pharmaceutical distribution.
Partnerships
- Tilray is party to a distribution agreement with Great North Distributors to provide sales force and wholesale/retail channel expertise required to efficiently distribute our adult-use products through each of the provincial/territorial cannabis control agencies, excluding Quebec where we utilize internal resources.
- On October 13, 2025, we entered into a strategic partnership for medical cannabis operations in Panama.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.
- Litigation, investigations and regulatory proceedings are costly, time-consuming and may divert the attention of management and other personnel from the operation of our business.
- General Business Risks and Risks Related to Our Financial Condition and Operations
- The Company's business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGC | Canopy Growth Corporation | USD 0.67 | ▲ 0.45% |
| ACB | Aurora Cannabis Inc. | USD 3.9 | ▼ 1.89% |
| CRON | Cronos Group Inc. Common Share | USD 3.33 | ▼ 3.48% |
| SNDL | SNDL Inc. | USD 1.3 | ▲ 0.39% |
| NIO | NIO Inc. | USD 3.3 | ▼ 0.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:18 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt